These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 21661405)

  • 1. Heterogeneity in primary colorectal cancer and its corresponding metastases: a potential reason of EGFR-targeted therapy failure?
    Li Z; Jin K; Lan H; Teng L
    Hepatogastroenterology; 2011; 58(106):411-6. PubMed ID: 21661405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy.
    Valtorta E; Misale S; Sartore-Bianchi A; Nagtegaal ID; Paraf F; Lauricella C; Dimartino V; Hobor S; Jacobs B; Ercolani C; Lamba S; Scala E; Veronese S; Laurent-Puig P; Siena S; Tejpar S; Mottolese M; Punt CJ; Gambacorta M; Bardelli A; Di Nicolantonio F
    Int J Cancer; 2013 Sep; 133(5):1259-65. PubMed ID: 23404247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.
    Siravegna G; Mussolin B; Buscarino M; Corti G; Cassingena A; Crisafulli G; Ponzetti A; Cremolini C; Amatu A; Lauricella C; Lamba S; Hobor S; Avallone A; Valtorta E; Rospo G; Medico E; Motta V; Antoniotti C; Tatangelo F; Bellosillo B; Veronese S; Budillon A; Montagut C; Racca P; Marsoni S; Falcone A; Corcoran RB; Di Nicolantonio F; Loupakis F; Siena S; Sartore-Bianchi A; Bardelli A
    Nat Med; 2015 Jul; 21(7):795-801. PubMed ID: 26030179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The role of KRAS gene mutation testing in colorectal cancer--a predictive biomarker of response to EGFR inhibitors therapy].
    Rako I; Jakić-Razumović J; Caban D; Sertić J; Katalinić D; Golem H; Plestina S
    Lijec Vjesn; 2011; 133(11-12):403-7. PubMed ID: 22329297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. miR-181a is associated with poor clinical outcome in patients with colorectal cancer treated with EGFR inhibitor.
    Pichler M; Winter E; Ress AL; Bauernhofer T; Gerger A; Kiesslich T; Lax S; Samonigg H; Hoefler G
    J Clin Pathol; 2014 Mar; 67(3):198-203. PubMed ID: 24098024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patients.
    Montagut C; Iglesias M; Arumi M; Bellosillo B; Gallen M; Martinez-Fernandez A; Martinez-Aviles L; Cañadas I; Dalmases A; Moragon E; Lema L; Serrano S; Rovira A; Rojo F; Bellmunt J; Albanell J
    Br J Cancer; 2010 Mar; 102(7):1137-44. PubMed ID: 20234366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
    László L
    Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications.
    Italiano A; Hostein I; Soubeyran I; Fabas T; Benchimol D; Evrard S; Gugenheim J; Becouarn Y; Brunet R; Fonck M; François E; Saint-Paul MC; Pedeutour F
    Ann Surg Oncol; 2010 May; 17(5):1429-34. PubMed ID: 20049644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?
    Rizzo S; Bronte G; Fanale D; Corsini L; Silvestris N; Santini D; Gulotta G; Bazan V; Gebbia N; Fulfaro F; Russo A
    Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S56-61. PubMed ID: 21129611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidermal growth factor receptor in CRC patients in the era of the RAS.
    Yanmaz MT; Demir G; Erdamar S; Keskin S; Aydin MF; Guner SI
    Hepatogastroenterology; 2015; 62(137):40-4. PubMed ID: 25911864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidermal growth factor receptor (EGFR) and KRAS mutations during chemotherapy plus anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer.
    Tougeron D; Cortes U; Ferru A; Villalva C; Silvain C; Tourani JM; Levillain P; Karayan-Tapon L
    Cancer Chemother Pharmacol; 2013 Aug; 72(2):397-403. PubMed ID: 23765179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR.
    Heinemann V; Stintzing S; Kirchner T; Boeck S; Jung A
    Cancer Treat Rev; 2009 May; 35(3):262-71. PubMed ID: 19117687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acquired KRAS mutations during progression of colorectal cancer metastases: possible implications for therapy and prognosis.
    Bouchahda M; Karaboué A; Saffroy R; Innominato P; Gorden L; Guettier C; Adam R; Lévi F
    Cancer Chemother Pharmacol; 2010 Aug; 66(3):605-9. PubMed ID: 20361188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KRAS mutations in non-small-cell lung cancer and colorectal cancer: implications for EGFR-targeted therapies.
    Maus MK; Grimminger PP; Mack PC; Astrow SH; Stephens C; Zeger G; Hsiang J; Brabender J; Friedrich M; Alakus H; Hölscher AH; Lara P; Danenberg KD; Lenz HJ; Gandara DR
    Lung Cancer; 2014 Feb; 83(2):163-7. PubMed ID: 24331409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
    Yen LC; Uen YH; Wu DC; Lu CY; Yu FJ; Wu IC; Lin SR; Wang JY
    Ann Surg; 2010 Feb; 251(2):254-60. PubMed ID: 20010090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
    Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
    J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KRAS testing in metastatic colorectal cancer: implications on the use of biologic agents.
    Bekaii-Saab T
    Clin Colorectal Cancer; 2009 Jul; 8(3):135-40. PubMed ID: 19632927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Morphological and molecular heterogeneity in colorectal neoplasms with K-RAS mutation. A report of two cases.
    Bösmüller H; Kranewitter W; Webersinke G; Rumpold H; Hackl M; Fend F
    Pathol Res Pract; 2011 Jun; 207(6):399-402. PubMed ID: 21536390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer.
    Neumann J; Zeindl-Eberhart E; Kirchner T; Jung A
    Pathol Res Pract; 2009; 205(12):858-62. PubMed ID: 19679400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical significance and the handling of KRAS testing on metastatic colorectal cancer].
    Kawamoto Y; Yoshino T
    Nihon Rinsho; 2011 Apr; 69 Suppl 3():346-50. PubMed ID: 22213982
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.